Ruxolitinib: gaining more than intended

Graeme Greenfield; Mary Frances McMullin

doi:10.1182/blood.2020005135

Ruxolitinib: gaining more than intended

Graeme Greenfield, Mary Frances McMullin

School of Medicine, Dentistry and Biomedical Sciences

Research output: Contribution to journal › Comment/debate › peer-review

161 Downloads (Pure)

Abstract

In this issue of Blood, Mollé et al demonstrate that on-target effects of ruxolitinib, a JAK1/2 inhibitor, reduce JAK2-mediated phosphorylation of STAT3 in the arcuate nucleus of the murine hypothalamus in response to feeding or exogenous leptin, proposing a novel mechanism for the weight gain observed with this drug.

Original language	English
Pages (from-to)	983-984
Number of pages	2
Journal	Blood
Volume	135
Issue number	13
DOIs	https://doi.org/10.1182/blood.2020005135
Publication status	Published - 26 Mar 2020

Access to Document

10.1182/blood.2020005135Licence: Unspecified

Ruxolitinib: gaining more than intended
© 2020 by The American Society of Hematology. This work is made available online in accordance with the publisher’s policies. Please refer to any applicable terms of use of the publisher.
Accepted author manuscript, 566 KBLicence: Unspecified

Cite this

@article{16b37ab6899545a7afbf2f2d82f2ed04,

title = "Ruxolitinib: gaining more than intended",

abstract = "In this issue of Blood, Moll{\'e} et al demonstrate that on-target effects of ruxolitinib, a JAK1/2 inhibitor, reduce JAK2-mediated phosphorylation of STAT3 in the arcuate nucleus of the murine hypothalamus in response to feeding or exogenous leptin, proposing a novel mechanism for the weight gain observed with this drug.",

author = "Graeme Greenfield and McMullin, {Mary Frances}",

year = "2020",

month = mar,

day = "26",

doi = "10.1182/blood.2020005135",

language = "English",

volume = "135",

pages = "983--984",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier B.V.",

number = "13",

}

TY - JOUR

T1 - Ruxolitinib: gaining more than intended

AU - Greenfield, Graeme

AU - McMullin, Mary Frances

PY - 2020/3/26

Y1 - 2020/3/26

N2 - In this issue of Blood, Mollé et al demonstrate that on-target effects of ruxolitinib, a JAK1/2 inhibitor, reduce JAK2-mediated phosphorylation of STAT3 in the arcuate nucleus of the murine hypothalamus in response to feeding or exogenous leptin, proposing a novel mechanism for the weight gain observed with this drug.

AB - In this issue of Blood, Mollé et al demonstrate that on-target effects of ruxolitinib, a JAK1/2 inhibitor, reduce JAK2-mediated phosphorylation of STAT3 in the arcuate nucleus of the murine hypothalamus in response to feeding or exogenous leptin, proposing a novel mechanism for the weight gain observed with this drug.

U2 - 10.1182/blood.2020005135

DO - 10.1182/blood.2020005135

M3 - Comment/debate

C2 - 32219353

SN - 0006-4971

VL - 135

SP - 983

EP - 984

JO - Blood

JF - Blood

IS - 13

ER -

Ruxolitinib: gaining more than intended

Abstract

Access to Document

Fingerprint

Cite this